Poor TTR undermines not only the efficacy of the therapy (more ischemic stroke), but also the safety (more intracranial bleeding).[4] Indeed, this might partly explain the prevailing perception of warfarin as an ineffective-and-yet-dangerous drug amongst Chinese clinicians, leading to gross underutilization of the therapy in Chinese and resulting is major missed opportunities for stroke prevention. The gene discussed is TTR; the disease is Stroke.